Triazavirin (TZV, Riamilovir) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[1]
Uses
It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity.[2][3][4] However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus,[5] and Forest-Spring Encephalitis virus,[6] and is also being investigated for potential application against Lassa fever and Ebola virus disease.[7][8][9][10][11] In February 2020, testing of triazavirin was started against SARS-CoV-2.[12][13][14]
^Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4.
^Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 52 (11–12): 18–20. PMID19275052.
^Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID23477247.
^Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 59 (1–2): 3–5. PMID25051708.
^Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV (2015). "[Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 60 (7–8): 11–3. PMID26863736.
^"Target: Ebola". Pravda. 2014-12-22. Retrieved 18 January 2015.
